Nile Pharmaceuticals results, Q2 2023
Net profit, assets, equity and cash flow for Q2 2023, against the same period a year earlier, from the published financial statements. fiscal year starts in July.
Net profit25.57 millionEGP · +9.6% vs the same period a year earlier
Total assets912 millionEGP · +17.9% vs the same period a year earlier
Shareholders' equity437 millionEGP · +14.1% vs the same period a year earlier
Operating cash flow38.01 millionEGP · +423.7% vs the same period a year earlier
In short
- Nile Pharmaceuticals's net profit for Q2 2023 was about 25.57 million EGP, up +9.6% from 23.34 million EGP in Q2 2022.
- Total assets at the end of Q2 2023 were about 912 million EGP, and shareholders' equity about 437 million EGP.
- Operating cash flow for Q2 2023 was positive at 38.01 million EGP.
Key lines against the same period a year earlier
This periodQ2 2022Change
Net profit25.57 million23.34 million+9.6%
Gross profit72.63 million67.91 million+7.0%
Total assets912 million774 million+17.9%
Total liabilities475 million391 million+21.6%
Shareholders' equity437 million383 million+14.1%
Total liabilities and equity912 million774 million+17.9%
Operating cash flow38.01 million-11.74 million+423.7%
Investing cash flow-52.09 million-2.3 million−2160.1%
Financing cash flow32.18 million-37.45 million+185.9%
Net change in cash18.1 million-51.5 million+135.1%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Nile Pharmaceuticals's Q1 2027 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy